Vimarsana
Biggest News Aggregation in the World

About Polyactiva News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from About Polyactiva. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In About Polyactiva Today - Breaking & Trending Today

PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology - Vimarsana News

PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology

Published: February 18, 2022

/PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with...

Source: prnewswire.com
Related Topics:
Brandon Capital Medical Research Commercialisation FundAbout PolyactivaBrandon CapitalMedical Research Commercialisation FundHealth Care Amp Hospitals Biotechnology Clinical Trials Amp Medical Discoveries
PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia Sustained Drug Delivery Technology - Vimarsana News

PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia Sustained Drug Delivery Technology

Published: February 18, 2022

- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically - Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma MELBOURNE, Australia,

Source: finanznachrichten.de
Related Topics:
San FranciscoUnited StatesKostenloser WertpapierhandelRussell TaitMichael CootePrezia Sustained Drug Delivery TechnologyPrnewswire Polyactiva Pty LtdBrandon Capital Medical Research Commercialisation FundHorizons ForumSecondary Efficacy Endpoints MetIntra Ocular PressureActiva Pty LtdPrimary Open Angle GlaucomaChief Executive OfficerAnnual GlaucomaAssociate Professor Michael CooteMelbourne Eye SpecialistsAbout PolyactivaBrandon CapitalMedical Research Commercialisation Fund
PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology - Vimarsana News

PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology

Published: February 17, 2022

/PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with...

Source: prnewswire.com
Related Topics:
Brandon Capital Medical Research Commercialisation FundAbout PolyactivaBrandon CapitalMedical Research Commercialisation FundHealth Care Amp Hospitals Biotechnology Clinical Trials Amp Medical Discoveries